TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04754152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: θ burst transcranial magnetic stimulation
Description: In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacotherapy
Description: Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
Study: NCT05697315

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No block was performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
Study: NCT06429839

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nimotuzumab with chemoradiotherapy
Description: Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
Study: NCT04839354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Hydrochloride
Description: One-time L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo (normal saline) loading dose (2ml/kg IV) + 1ml/kg IV TID
Study: NCT05511675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold application
Description: ISO-BALL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold application
Description: ISO-BALL
Study: NCT02649530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WNT974
Study: NCT06339333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Now GAIN Later
Description: ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Waitlist Group
Study: NCT04521335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
Study: NCT05160415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten
Description: Daily oral dose
Study: NCT04521335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Description: Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
Study: NCT05420090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Banana arm
Description: Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milk arm
Description: Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
Study: NCT05382104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Study: NCT05133375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
Study: NCT06196788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg per square meter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 120 mg per square meter of body-surface area
Study: NCT06552819

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05992298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 T MRI vs 3 T MRI
Description: Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
Study: NCT04225949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey 1
Description: survey with one version of depiction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey 2
Description: survey with one version of depiction
Study: NCT05061797

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Thermogenic Energy Drink - Active Study Product Formula
Description: The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
Study: NCT05485519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: (1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
Study: NCT05061797

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
Study: NCT05980130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behavior Therapy
Description: The RFCBT exclusively addresses one possible mechanism underlying depression, rumination. In general, a participant and their therapist will identify when the participant ruminates in an unhelpful manner, what triggers the rumination, what function the rumination fulfills for the participant, and how the participant already does to stop ruminating. Building on this knowledge both together will change the environment to reduce the likelihood of the participant to ruminate, use consciously strategies to stop rumination when it occurs, and replace rumination by more helpful strategies. In the proposed single subject study, the participant and the therapist will meet in person or using a UofL approved video platform up to 18 times for 50-minutes.
Study: NCT04703140

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test vs PCR
Description: 2 nasopharyngeal swabs taken for PCR and COVIDISC
Study: NCT05963438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior retraction
Description: After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior retraction
Description: After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
Study: NCT05727241

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
Study: NCT05973643

Intervention type: OTHER
Group type: OTHER
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process.
Study: NCT05654467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)
Description: The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
Study: NCT05176158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 MG
Description: Pill at morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 MG
Description: Pill at night
Study: NCT05480592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10380
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10380
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a tablet
Study: NCT05756491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 months of inclusion of unaccompanied patients
Description: inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18 months of inclusion of unaccompanied patients
Description: inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 months of inclusion of unaccompanied patients
Description: inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 months of inclusion of unaccompanied patients
Description: inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
Study: NCT06081868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of toothbrush/toothpaste/fluoride varnish
Description: Children receive information about the use of toothbrush/toothpaste/fluoride varnish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on nutrition/oral hygiene
Description: Children receive education on nutrition/oral hygiene.
Study: NCT06289842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Description: TMS Therapy System with Theta Burst Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Description: TMS Therapy System with Theta Burst Stimulation
Study: NCT05480592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet
Study: NCT05747521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotinib hydrochloride combined with adriamycin
Description: To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
Study: NCT06142864

Intervention type: OTHER
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05067868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replagal
Description: Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
Study: NCT00917202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylenblue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylenblue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylenblue
Study: NCT05246007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
Study: NCT05511818

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rest Study Product Usage
Description: Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
Study: NCT05821348

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: salivary markers
Description: a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
Study: NCT05780593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined Board Standing
Description: The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined Board Standing
Description: The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.